

In the Claims:

Please cancel Claims 1, 3-11, 15-18, 23-39, 78, 79 and 84-95, without prejudice, and amend the pending claims as follows:

1.-44. (Canceled)

45. (Currently amended) ~~A therapeutic composition or anti-inflammatory~~ An anabolic medicament for treating a damaged tissue, the tissue being characterized, when healthy, by a characteristic amino acid molar ratio for the healthy tissue per se, or for at least one peptide, polypeptide, or protein thereof, the medicament comprising:

a) at least one mucopolysaccharide extracellular matrix compound in an amount effective in the damaged tissue as an anti-neo-inflammatory and anti-neo-angiogenetic agent,

b) at least one polar surface active lipid; and

c) ~~at least one optically pure~~ a plurality of essential L-amino acid acids having an alpha carbon, the amino acids being present at a molar ratio corresponding to the characteristic amino acid molar ratio, no more than 10% of the amino acid being in dextrorotary form.

46. (Currently amended) ~~The therapeutic composition or anti-inflammatory~~ medicament according to claim 45,

wherein said extracellular matrix compound is synthetically produced.

47. (Currently amended) ~~The therapeutic composition or anti-inflammatory~~ medicament according to claim 45,

wherein said extracellular matrix compound is obtained from a cellular or tissue sources source.

48. (Currently amended) ~~The therapeutic composition or anti-inflammatory~~ medicament according to claim 45,

wherein said polar surface active lipid is obtained from a cellular or tissue sources source.

49. (Currently amended) ~~The therapeutic composition or anti-inflammatory~~ medicament according to claim 45,

wherein said polar surface active lipid is synthetically produced.

50. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45, wherein said ~~optically pure essential L-amino acid is at least one of said amino acids~~ is synthetically produced.

51. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45, wherein said ~~optically pure essential L-amino acid is at least one of said amino acids~~ is obtained from a cellular or tissue sources source.

52. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 47,

wherein said cellular or tissue ~~sources are cell membranes, tissues, or organs~~ source is selected from the group consisting of a cell membrane, a tissue, and an organ.

53. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45,

wherein said extracellular matrix compound is selected from the group consisting of ~~glycosaminoglycans~~ a glycosaminoglycan, ~~collagens~~ a collagen, cartilage, ~~chondroitin~~ chondroitin sulfate, ~~glycoproteins~~ a glycoprotein, and ~~proteoglycans~~ a proteoglycan.

54. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45, wherein said polar surface active ~~lipids are~~ lipid is selected from the group consisting of ~~phospholipids~~ a phospholipid, ~~glycolipids~~ a glycolipid, and ~~lipoproteins~~ a lipoprotein.

55. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45, wherein said amino ~~acids are~~ acid comprises an aliphatic ~~amino acids~~ side chain on the alpha carbon.

56. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 55, wherein said aliphatic ~~amino acids contain~~ side chain is a short chain fatty ~~acids~~ acid.

57. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 56, wherein said ~~amino acids contain ammoniated~~ short chain fatty acids at the alpha-carbon position acid is ammoniated.

58. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim ~~56~~ 45, wherein said ~~amino acids are~~ amino acid is selected from the group consisting of glycine, L-alanine, L-leucine, L-isoleucine, L-threonine, L-cysteine, L-methionine, L-cystine, L-serine, L-valine, and combinations thereof.

59. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 58, ~~wherein said therapeutic composition or anti-inflammatory medicament contains amino acids~~ comprising amino acids present at a molar ratio corresponding to a characteristic molar ratio of amino acids in cyclosporin.

60. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 59, wherein said amino acids present at the molar ratio corresponding to the characteristic molar ratio of amino acids in cyclosporin are glycine, L-alanine, L-leucine, and L-valine.

61. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 57, wherein said ~~amino acid contains butyric acid as the short chain fatty acid~~ is butyric acid.

62. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 61, wherein said amino acid is L-valine.

63. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 61, wherein said amino acid is L-methionine.

64. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 61, wherein said amino acid is gamma amino butyric acid.

65. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45, further comprising a sterile vehicle.

66. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 48, wherein said cellular or tissue ~~sources~~ source is selected from the group consisting of a cell membrane, a tissue, and an organ.

67. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 51, wherein said cellular or tissue ~~sources~~ source is selected from the group consisting of a cell membrane, a tissue, and an organ.

68. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 49, wherein said polar surface active ~~lipids are~~ lipid is selected from the group consisting of ~~phospholipids~~ a phospholipid, ~~glycolipids~~ a glycolipid, and ~~lipoproteins~~ a lipoprotein.

69. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 48, wherein said polar surface active ~~lipids are~~ lipid is selected from the group consisting of ~~phospholipids~~ a phospholipid, ~~glycolipids~~ a glycolipid, and ~~lipoproteins~~ a lipoprotein.

70. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 48, wherein at least one extracellular matrix compound, at least one polar surface active lipid, and at least one ~~optically pure essential L-amine~~ amino acid associate through a molecular bonding forces force.

71. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 70, wherein said molecular bonding ~~forces are~~ force is selected from the group consisting of electron affinity, van der Waals ~~forces~~, ~~or and~~ zwitterionic.

72. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 59, wherein components of said ~~therapeutic composition or anti-inflammatory~~ medicament associate through a molecular bonding forces force.

73. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 70, wherein said molecular bonding ~~forces are~~ force is selected from the group consisting of electron affinity, van der Waals ~~forces, or~~ and zwitterionic.

74. (Currently amended) The ~~composition~~ medicament according to claim 45, further comprising ~~one or more of the following at least one of:~~ (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; ~~or~~ and (j) collagen.

75. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 59, further comprising ~~one or more of the following at least one of:~~ (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; ~~or~~ and (j) collagen.

76. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 48, further comprising ~~one or more of the following at least one of:~~ (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; ~~or~~ and (j) collagen.

77. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 73, further comprising ~~one or more of the following at least one of:~~ (a) at least one mineral; (b) at least one vitamin; (c) at least one antioxidant; (d) omega-3 oil(s); (e) zinc, (f) zinc oxide; (g) Vitamin A; (h) chondroitin sulfate; (i) cartilage; ~~or~~ and (j) collagen.

78 - 95. Cancelled

96. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45 ~~wherein said optically pure~~ amino acid is selected from the group consisting of L-histidine, L-isoleucine, L-leucine, L-lysine, L-methionine, L-phenylalanine, L-threonine, L-tryptophan, and L-valine.

97. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45 wherein said ~~optically pure~~ further comprising an amino acid is selected from the group consisting of L-alanine, L-arginine, L-asparagine, L-cysteine, L-glutamic acid, L-glutamine, L-glutamate, L-proline, L-serine, glycine, L-threonine, L-tyrosine, L-aurine, L-gamma amino butyric acid, and L-carnitine.

98. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45 further comprising a fatty acid selected from the group consisting of linoleic fatty acids acid or and linolenic fatty acids acid.

99. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 45, wherein the ~~composition comprises a combination of optically pure essential-amino acids~~ in a ratio of four moles L-leucine:two moles L-alanine: two moles L-valine: one mole methionine:one mole L-gamma amino butyric acid: one mole L-betaine: one mole glycine.

100. (Currently amended) The ~~therapeutic composition or anti-inflammatory~~ medicament according to claim 99, further comprising a fatty acid selected from the group consisting of linoleic fatty acids acid or and linolenic fatty acids acid.